Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 6/20 | 0.35 |
| ▸ | BACE1 | P56817 | 6/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 5/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5431785 | 0.90 | CTSD (0.36) | CTSDBACE1USP2ALDH1A1BACE2 | |
| SCHEMBL5429008 | 0.88 | BACE1 (0.36) | CTSDBACE1LMNAUSP2POLB | |
| SCHEMBL5434730 | 0.73 | USP2 (0.34) | CTSDBACE1USP2ALDH1A1BACE2 | |
| SCHEMBL5443586 | 0.69 | LMNA (0.36) | LMNAPOLBALDH1A1NPC1RAB9A | |
| SCHEMBL5429111 | 0.66 | LMNA (0.36) | LMNAUSP2ALDH1A1TSHRMAPT | |
| SCHEMBL5429003 | 0.66 | CYP1A2 (0.35) | CTSDBACE1LMNAPOLBALDH1A1 | |
| SCHEMBL5434946 | 0.64 | NPC1 (0.43) | CTSDBACE1USP2ALDH1A1BACE2 | |
| SCHEMBL5184629 | 0.61 | HSD17B10 (0.38) | USP2POLBALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL5224792 | 0.61 | CTSD (0.56) | CTSDBACE1ALDH1A1BACE2NPC1 | |
| SCHEMBL9208078 | 0.60 | GAA (0.52) | LMNAPOLBALDH1A1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253198-B2 | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | CTSD 384/4885BACE1 3/4885LMNA 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.